Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Molecule 1 (ICAM-1 and VCAM-1)

Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule 1 (VCAM-1) are critical transmembrane glycoproteins belonging to the immunoglobulin superfamily that mediate leukocyte adhesion and transendothelial migration [1, 2]. ICAM-1 (CD54) is constitutively expressed at low levels on endothelial cells and various immune cells, but is significantly upregulated by pro-inflammatory cytokines like TNF-alpha and IL-1 to facilitate stable leukocyte arrest via the integrins LFA-1 and Mac-1 [3, 4]. VCAM-1 (CD106) is primarily induced on activated vascular endothelial cells and bone marrow stromal cells, where it interacts with the integrin VLA-4 (alpha4beta1) to promote the recruitment of lymphocytes, monocytes, and eosinophils [2, 4]. In disease states, these molecules play pivotal roles in the pathogenesis of atherosclerosis, autoimmune disorders, and cancer metastasis by enabling the infiltration of inflammatory cells into tissues or the docking of circulating tumor cells to the vascular wall [3, 4]. Therapeutic strategies targeting these pathways include monoclonal antibodies and small molecules, such as Lifitegrast and Natalizumab, which block the CAM-integrin interface to reduce pathological inflammation and tumor spread [5, 6]. The expression of these molecules on stromal cells also contributes to a supportive microenvironment for tumor growth and chemoresistance [4].

Other names

CD54CD106ICAM1VCAM1Major group rhinovirus receptorINCAM-100Antigen identified by monoclonal antibody 1G11

Inhibition of leukocyte-endothelial adhesion and migration by blocking the interaction between cell adhesion molecules (ICAM-1, VCAM-1) and their respective integrin ligands, such as LFA-1 (alphaLbeta2) and VLA-4 (alpha4beta1) [5, 6].